Gracell Biotechnologies, a Chinese biotech start-up that focuses on cellular gene therapy, has raised a US$85 million series B financing round led by Singapore’s state investment firm Temasek, according to an announcement released on Monday.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?